natgillin/translations-raw huggingface dataset:
Transient skin redness, itching or other signs of discomfort at the application site have been reported rarely and usually disappear without any treatment and within 24 hours after using the veterinary medicine. 
Redko se lahko na mestu nanosa pojavi prehodna rdečina, praskanje ali drugi znaki neugodja, ki navadno spontano izginejo znotraj 24 ur po nanosu zdravila za uporabo v veterinarski medicini.
Following a single administration, the veterinary medicinal product will prevent infestation for one month. 
Po enkratnem nanosu bo zdravilo en mesec preprečevalo okužbo.
Dogs over 4 kg and up to 10 kg body weight 
Psi nad 4 kg in do 10 kg telesne mase
Dogs over 10 kg and up to 40 kg body weight 
Psi nad 10 kg in do 40 kg telesne mase
Each ml contains 54 mg dinotefuran, 4.84 mg pyriproxyfen and 397 mg permethrin. 
KAKOVOSTNA IN KOLIČINSKA SESTAVA Učinkovine: Vsak ml vsebuje 54 mg dinotefurana, 4,84 mg piriproksifena in 397 mg permetrina.
The veterinary medicine repels (prevents biting) flying insects such as sand flies (Phlebotomus perniciosus), mosquitoes (Culex pipiens, Aedes aegypti) and stable flies (Stomoxys calcitrans) for one month after use. 
Peščene muhe, komarji, hlevske muhe: Zdravilo za uporabo v veterinarski medicini odganja (preprečuje ugrize) leteče insekte kot so peščene muhe (Phlebotomus perniciosus), komarji (Culex pipiens, Aedes aegypti) in hlevske muhe (Stomoxys calcitrans) en mesec po nanosu.
4a recommendation: Gently squeeze the applicator and apply the veterinary medicine to the skin along the dog's back, beginning between the shoulder blades, in the number of spots and order shown in the diagrams below and squeezing until the applicator is empty. 
4a priporočila: Rahlo stisnite kapalko in nanesite zdravilo na kožo vzdolž hrbta, pričnite med lopaticama in zdravilo nanesite na več mest, kot kaže diagram spodaj in kapalko stiskajte, dokler ni prazna.
Other precautions 
Drugi previdnostni ukrepi:
It also kills mosquitoes (Aedes aegypti) and stable flies for one month after use. 
Ubije tudi komarje (Aedes aegypti) in hlevske muhe (Stomoxys calcitrans) en mesec po nanosu.
Insects do not have to ingest dinotefuran, it kills by contact. 
Dinotefuran ubije preko kontakta in ga insektu ni potrebno zaužiti.
Care should be taken to avoid contact between the veterinary medicine and the eyes of the dog. 
Izogibajte se stiku zdravila z očmi psa.
Dogs over 40 kg body weight 
Psi nad 40 kg telesne mase
Dogs from 1.5 to 4 kg body weight 
Psi 1,5 do 4 kg telesne mase
AUTHORISATION 
Inkompatibilnosti
Repels (prevents biting) flying insects such as sand flies, mosquitoes and stable flies for 1 month. 
Zdravilo ima repelentni učinek (preprečuje ugrize) na leteče insekte, kot so peščene muhe, komarji in hlevske muhe, en mesec po nanosu.
1 applicator of 
1 kapalka
The veterinary medicinal product has persistent acaricidal and repellent efficacy against tick infestations (Rhipicephalus sanguineus and Ixodes ricinus for one month, and Dermacentor reticulatus for up to three weeks). 
(Rhipicephalus sanguineus in Ixodes ricinus en mesec in Dermacentor retuculatus do treh tednov).
Prevention of flea multiplication for 2 months. 
Zdravilo preprečuje razmnoževanje bolh dva meseca po nanosu.
Vectra 3D spot-on (1.5-4 kg) Vectra 3D spot-on (> 4-10 kg) Vectra 3D spot-on (> 10-25 kg) Vectra 3D spot-on (> 25-40 kg) Vectra 3D spot-on (> 40 kg) 
Vectra 3D kožni nanos (1,5-4 kg) Vectra 3D kožni nanos (> 4-10 kg) Vectra 3D kožni nanos (> 10-25 kg) Vectra 3D kožni nanos (> 25-40 kg) Vectra 3D kožni nanos (> 40 kg)
Kills mosquitoes and stable flies for 1 month. 
Zdravilo ubija komarje in hlevske muhe en mesec po nanosu.
Weight of dog (kg) 
Telesna masa psa (kg)
1 spot-on applicator 3 spot-on applicators 4 spot-on applicators 6 spot-on applicators 12 spot-on applicators 24 spot-on applicators 48 spot-on applicators 
1 kapalka za kožni nanos 3 kapalke za kožni nanos 4 kapalke za kožni nanos 6 kapalk za kožni nanos 12 kapalk za kožni nanos 24 kapalk za kožni nanos 48 kapalk za kožni nanos
for dogs 1.5-4 kg 
Psi 1,5-4 kg rumena
The attachment of a single tick after treatment cannot be excluded. 
Ni mogoče izključiti možnosti, da se posamezni klopi prisesajo tudi po nanosu zdravila.
Vectra 3D for dogs 1.5-4 kg for dogs > 4-10 kg 
Vectra 3D za pse 1,5-4 kg psi > 4-10 kg modro zelena
The actives act directly on the pets' coat without any need to infiltrate the blood flow. 
Prehod učinkovin v krvni obtok ni potreben, saj delujejo neposredno na dlaki hišnih ljubljenčkov.
Vectra 3D for dogs > 25-40 kg for dogs > 40 kg 
Vectra 3D za pse > 25-40 kg psi > 40 kg rdeča
4.9 Amounts to be administered and administration route Dosage: 
4.9 Odmerjanje in pot uporabe
Vectra 3D for dogs > 4-10 kg for dogs > 10-25 kg 
Vectra 3D za pse > 4-10 kg psi > 10-25 kg modra
Special precautions for use in animals: 
Posebni previdnostni ukrepi za uporabo pri živalih Samo za zunanjo uporabo.
Vectra 3D for dogs > 10-25 kg for dogs > 25-40 kg Purple 
Vectra 3D za pse > 10-25 kg psi > 25-40 kg vijolična 4,7
Method and route of administration 
Način in pot uporabe:
Vectra 3D spot-on solution for dogs 1.5-4 kg Vectra 3D spot-on solution for dogs > 4-10 kg Vectra 3D spot-on solution for dogs > 10-25 kg Vectra 3D spot-on solution for dogs > 25-40 kg Vectra 3D spot-on solution for dogs > 40 kg dinotefuran / pyriproxyfen / permethrin 
Vectra 3D kožni nanos, raztopina za pse 1,5-4 kg Vectra 3D kožni nanos, raztopina za pse > 4-10 kg Vectra 3D kožni nanos, raztopina za pse > 10-25 kg Vectra 3D kožni nanos, raztopina za pse > 25-40 kg Vectra 3D kožni nanos, raztopina za pse > 40 kg dinotefuran/piriproksifen/permetrin
Do not eat, drink or smoke while handling the veterinary medicinal product. 
Posebni previdnostni ukrepi, ki jih mora izvajati oseba, ki živalim daje zdravilo: Ne jejte, pijte ali kadite, ko delate z zdravilom za uporabo v veterinarski medicini.
Red For the full list of excipients, see section 6.1. 
Psi > 25-40 kg vijolična Psi > 40 kg rdeča Za celoten seznam pomožnih snovi glejte poglavje 6.1.
PACKAGE LEAFLET: Vectra 3D spot-on solution for dogs 1.5-4 kg Vectra 3D spot-on solution for dogs > 4-10 kg Vectra 3D spot-on solution for dogs > 10-25 kg Vectra 3D spot-on solution for dogs > 25-40 kg Vectra 3D spot-on solution for dogs > 40 kg 
NAVODILO ZA UPORABO Vectra 3D kožni nanos, raztopina za pse 1,5-4 kg Vectra 3D kožni nanos, raztopina za pse > 4-10 kg Vectra 3D kožni nanos, raztopina za pse > 10-25 kg Vectra 3D kožni nanos, raztopina za pse > 25-40 kg Vectra 3D kožni nanos, raztopina za pse > 40 kg
Yellow for dogs > 4-10 kg 
Psi > 4-10 kg modro zelena Psi > 10-25 kg modra
Blue for dogs > 25-40 kg 
Psi > 25-40 kg vijolična Psi > 40 kg rdeča
Vectra 3D spot-on solution for dogs 1.5-4 kg Vectra 3D spot-on solution for dogs > 4-10 kg Vectra 3D spot-on solution for dogs > 10-25 kg Vectra 3D spot-on solution for dogs > 25-40 kg Vectra 3D spot-on solution for dogs > 40 kg 
Vectra 3D kožni nanos, raztopina za pse 1,5-4 kg Vectra 3D kožni nanos, raztopina za pse > 4-10 kg Vectra 3D kožni nanos, raztopina za pse > 10-25 kg Vectra 3D kožni nanos, raztopina za pse > 25-40 kg Vectra 3D kožni nanos, raztopina za pse > 40 kg
Worsening of diabetic retinopathy has also been observed and will be further investigated. 
Opaženo je bilo tudi poslabšanje diabetične retinopatije; to bo nadalje proučeno.
What measures are being taken to ensure the safe and effective use of Ozempic? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Ozempic?
The full EPAR for Ozempic can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Ozempic je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
These are mild or moderate in severity and of short duration. 
Ti neželeni učinki so blagi ali zmerni in so kratkotrajni.
The starting dose of Ozempic is 0.25 mg once a week. 
Začetni odmerek zdravila Ozempic je 0,25 mg enkrat na teden.
This is a summary of the European public assessment report (EPAR) for Ozempic. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Ozempic.
Other information about Ozempic 
Druge informacije o zdravilu Ozempic
It acts in the same way as GLP-1 (a hormone produced in the gut) by increasing the amount of insulin that the pancreas releases in response to food. 
To pomeni, da deluje enako kot GLP-1 (v črevesju proizvedeni hormon), in sicer tako, da povečuje količino insulina, ki ga kot odziv na zaužito hrano izloči trebušna slinavka.
What is Ozempic and what is it used for? 
Kaj je zdravilo Ozempic in za kaj se uporablja?
The active substance in Ozempic, semaglutide, is a ‘GLP-1 receptor agonist'. 
Zdravilna učinkovina v zdravilu Ozempic, semaglutid, je agonist receptorjev za GLP-1.
What benefits of Ozempic have been shown in studies? 
Kakšne koristi je zdravilo Ozempic izkazalo v študijah?
What are the risks associated with Ozempic? 
Kakšna tveganja so povezana z zdravilom Ozempic?
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Ozempic have been included in the summary of product characteristics and the package leaflet. 
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Ozempic upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
Ozempic can be used on its own in patients who cannot take metformin (another diabetes medicine). 
Zdravilo Ozempic se lahko uporablja kot samostojno zdravilo pri bolnikih, ki ne morejo jemati metformina (drugega zdravila za zdravljenje sladkorne bolezni).
Ozempic in these studies compared favourably with other treatments, sitagliptin, exenatide and insulin glargine (which led to reductions of 0.55, 0.92, 0.83 percentage points respectively) and placebo (reductions of up to 0.09 percentage points). 
Izidi zdravljenja z zdravilom Ozempic so bili v teh študijah boljši od drugih zdravil - sitagliptina, eksenatida in insulina glargina (uporaba katerih je privedla do zmanjšanja za 0,55, 0,92 oz. 0,83 odstotne točke) - ter placeba (zmanjšanje za do 0,09 odstotne točke).
For more information about treatment with Ozempic, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Ozempic preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
The European Medicines Agency concluded that the benefits of Ozempic seen in studies outweighed its risk and recommended it be approved for use in the EU. 
Evropska agencija za zdravila je zaključila, da so v študijah izkazane koristi zdravila Ozempic večje od z njim povezanih tveganj, in priporočila, da se odobri za uporabo v EU.
It is not intended to provide practical advice on how to use Ozempic. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
If needed, the dose can be further increased up to a maximum of 1 mg once a week. 
Ta odmerek je treba po štirih tednih povečati na 0,5 mg. Odmerek se po potrebi lahko dodatno poveča na največ 1 mg enkrat na teden.
A further study in over 3,000 diabetes patients at high risk of heart problems showed that overall, heart attack, stroke or death occurred less frequently in patients treated with Ozempic (6.6%) than with placebo (8.9%). 
Še ena študija z več kot 3 000 bolniki s sladkorno boleznijo in velikim tveganjem za težave s srcem je pokazala, da je skupno do srčnega infarkta, možganske kapi ali smrti pri bolnikih, zdravljenih z zdravilom Ozempic, prišlo manj pogosto (6,6 %) kot pri bolnikih, zdravljenih s placebom (8,9 %).
Five studies in over 4,000 patients showed that Ozempic lowered levels of HbA1c (a measure of blood glucose) by between 1.2 and 1.8 percentage points over 10 to 13 months. 
Pet študij z več kot 4 000 bolniki je pokazalo, da zdravilo Ozempic v 10- do 13-mesečnem obdobju zniža koncentracijo HbA1c (merilo za glukozo v krvi) za od 1,2 do 1,8 odstotne točke.
Ozempic is a diabetes medicine used with diet and exercise to treat adults whose type 2 diabetes is not satisfactorily controlled. 
Ozempic je zdravilo za zdravljenje sladkorne bolezni, ki se uporablja skupaj z dieto in telesno vadbo za zdravljenje odraslih, pri katerih sladkorna bolezen tipa 2 ni zadovoljivo uravnana.
It is injected under the skin of the belly, the thigh or the upper arm. 
Injicira se v podkožje, in sicer v trebuh, stegno ali nadlaket.
Studies showed that Ozempic is effective at lowering blood glucose levels and reducing the risk of health complications in patients with type 2 diabetes. 
Študije so pokazale, da zdravilo Ozempic učinkovito znižuje koncentracijo glukoze v krvi in zmanjšuje tveganje za zdravstvene zaplete pri bolnikih s sladkorno boleznijo tipa 2.
Why is Ozempic approved? 
Zakaj je bilo zdravilo Ozempic odobreno?
For practical information about using Ozempic, patients should read the package leaflet or contact their doctor or pharmacist. 
Za praktične informacije o uporabi zdravila Ozempic naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
Ozempic is available as a solution for injection in prefilled pens and can only be obtained with a prescription. 
Zdravilo Ozempic je na voljo v obliki raztopine za injiciranje v napolnjenih injekcijskih peresnikih, njegovo predpisovanje in izdaja pa je le na recept.
Ozempic was also shown to be effective at reducing the occurrence of serious health complications associated with diabetes such as heart attack and stroke. 
Izkazalo se je tudi, da zdravilo Ozempic učinkovito zmanjšuje pojav resnih zdravstvenih zapletov, povezanih s sladkorno boleznijo, kot sta srčni infarkt in možganska kap.
This helps with the control of blood glucose levels. 
To pomaga pri uravnavanju koncentracije glukoze v krvi.
The most common side effects with Ozempic (which may affect more than 1 in 10 people) include problems with the digestive system, such as diarrhoea, vomiting and nausea (feeling sick). 
Najpogostejši neželeni učinki zdravila Ozempic (ki se lahko pojavijo pri več kot 1 bolniku od 10) so prebavne težave, kot so driska, bruhanje in navzea (siljenje na bruhanje).
For the full list of all side effects and restrictions with Ozempic, see the package leaflet. 
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Ozempic glejte navodilo za uporabo.
In addition, the results indicated that treatment with Ozempic was associated with a beneficial fall in body weight. 
Poleg tega so rezultati pokazali, da je zdravljenje z zdravilom Ozempic povezano s koristnim zmanjšanjem telesne mase.
Side effects affecting the digestive system are considered to be manageable. 
Neželeni učinki na prebavila naj bi bili obvladljivi.
When looking at the three ‘events' separately, fewer patients taking Ozempic had a heart attack or stroke, but rates of death from heart problems were similar in the two groups. 
Ločena analiza teh treh „dogodkov“ je pokazala, da je do srčnega infarkta ali možganske kapi prišlo pri manj bolnikih, ki so jemali zdravilo Ozempic, umrljivost zaradi težav s srcem pa je bila v obeh skupinah podobna.
Treatment with Ozempic also led to weight loss, which is considered beneficial in patients with diabetes. 
Zdravljenje z zdravilom Ozempic je privedlo tudi do zmanjšanja telesne mase, kar se pri bolnikih s sladkorno boleznijo šteje kot koristno.
Ozempic was shown to be effective at controlling blood glucose levels. 
Zdravilo Ozempic se je izkazalo kot učinkovito pri uravnavanju koncentracije glukoze v krvi.
How is Ozempic used? 
Kako se zdravilo Ozempic uporablja?
Ozempic contains the active substance semaglutide. 
Zdravilo Ozempic vsebuje zdravilno učinkovino semaglutid.
Serious worsening of diabetic retinopathy (damage to the retina, the light sensitive membrane at the back of the eye) is common (it may affect up to 1 in 10 people). 
Pogosto (pojavlja se pri največ 1 bolniku od 10) je resno poslabšanje diabetične retinopatije (poškodbe mrežnice, tj. na svetlobo občutljive membrane na očesnem ozadju).
How does Ozempic work? 
Kako zdravilo Ozempic deluje?
720 ELISA Units 
720 ELISA enot
1 pre-filled syringe + 
1 napolnjena injekcijska brizga + 1 igla
1 dose (1 ml) contains: Hepatitis A virus (inactivated)1,2 
Virus hepatitisa A (inaktivirani)
MA (EU) Number (Invented) name 
(Izmišljeno) ime Jakost
What measures are being taken to ensure the safe and effective use of Glustin? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Glustin?
Further studies also looked at long-term use of Glustin. 
V nadaljnjih študijah so proučevali tudi dolgoročno uporabo zdravila Glustin.
The full EPAR for Glustin can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Glustin je na voljo na spletni strani agencije:ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
The European Commission granted a marketing authorisation valid throughout the European Union, for Glustin on 11 October 2000. 
Evropska komisija je dovoljenje za promet z zdravilom Glustin, veljavno po vsej Evropski uniji, izdala 11. oktobra 2000.
It is used in addition to diet and exercise as follows: 
Uporablja se kot dodatek k ustrezni prehrani in telesni vadbi, in sicer:
Treatment with Glustin should be reviewed after three to six months, and discontinued in patients who are not deriving sufficient benefit. 
Zdravljenje z zdravilom Glustin je treba ponovno oceniti po treh do šest mesecih in ga pri bolnikih, ki od njega nimajo zadostne koristi, ukiniti.
Other information about Glustin: 
Druge informacije o zdravilu Glustin:
This is a summary of the European public assessment report (EPAR) for Glustin. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Glustin.
Almost 7,000 patients received Glustin in all of the studies combined. 
V vseh študijah skupaj je zdravilo Glustin prejemalo skoraj 7 000 bolnikov.
As a consequence, the blood glucose levels are reduced and this helps to control type 2 diabetes. 
Posledično se raven glukoze v krvi zniža, kar pripomore k nadzoru sladkorne bolezni tipa 2.
It must also not be used in patients who have or have had bladder cancer or those with blood in the urine that has not yet been investigated. 
Poleg tega ga ne smejo uporabljati bolniki, ki imajo ali so imeli raka sečnega mehurja, ali bolniki, ki imajo kri v urinu, vendar preiskave v zvezi s tem še niso bile opravljene.
What benefit has Glustin shown during the studies? 
Kakšne koristi je zdravilo Glustin izkazalo med študijami?
What is the risk associated with Glustin? 
Kakšna tveganja so povezana z zdravilom Glustin?
For more information about treatment with Glustin, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Glustin preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Glustin is a medicine that contains the active substance pioglitazone. 
Glustin je zdravilo, ki vsebuje zdravilno učinkovino pioglitazon.
The most common side effects with Glustin (seen in between 1 and 10 patients in 100) are upper respiratory tract infection (colds), hypoaesthesia (reduced sense of touch), visual disturbance, bone fractures and increased weight. 
Najpogostejši neželeni učinki zdravila Glustin (opaženi pri 1 do 10 bolnikih od 100) so okužba zgornjih dihal (prehladi), hipestezija (zmanjšan občutek za dotik), motnje vida, zlomi kosti in povečanje telesne mase.
The doses of Glustin may need to be adjusted when given with some other medicines such as gemfibrozil (used to lower cholesterol) or rifampicin (an antibiotic used to treat tuberculosis). 
Odmerke zdravila Glustin bo morda treba prilagoditi, če se jemlje skupaj z nekaterimi drugimi zdravili, kot sta gemfibrozil (ki se uporablja za zniževanje holesterola) ali rifampicin (antibiotik, ki se uporablja za zdravljenje tuberkuloze).
The CHMP decided that Glustin's benefits are greater than its risks and recommended that it be given marketing authorisation. 
Odbor CHMP je zaključil, da so koristi zdravila Glustin večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
If Glustin is used in combination with other diabetes medicines, other side effects may occur. 
Če se zdravilo Glustin uporablja v kombinaciji z drugimi zdravili proti sladkorni bolezni, se lahko pojavijo še drugi neželeni učinki.
The active substance in Glustin, pioglitazone, makes cells (fat, muscle and liver) more sensitive to insulin, which means that the body makes better use of the insulin it produces. 
Zdravilna učinkovina zdravila Glustin, pioglitazon, poveča občutljivost celic (maščevja, mišic in jeter) za insulin, kar pomeni, da telo bolje izrablja insulin, ki ga proizvaja.
Type 2 diabetes is a disease in which the pancreas does not make enough insulin to control the level of glucose in the blood or when the body is unable to use insulin effectively. 
Sladkorna bolezen tipa 2 je bolezen, pri kateri trebušna slinavka ne tvori dovolj insulina za uravnavanje ravni glukoze v krvi ali pri kateri ga telo ne more učinkovito izrabiti.
Glustin must not be used in patients who have problems with their liver, patients who have had heart failure (when the heart does not work as well as it should) or patients with diabetic ketoacidosis (a complication of diabetes). 
Prav tako ga ne smejo uporabljati bolniki, ki imajo težave z jetri, bolniki s srčnim popuščanjem (pri katerih srce ne deluje, kot bi moralo) ali bolniki z diabetično ketoacidozo (zapletom pri sladkorni bolezni).
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Glustin. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Glustin, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
Glustin is used to treat type 2 diabetes in adults (aged 18 years or over), particularly those who are overweight. 
Zdravilo Glustin se uporablja za zdravljenje sladkorne bolezni tipa 2 pri odraslih (starejših od 18 let), zlasti tistih s prekomerno telesno maso.
The studies measured the level of a substance in the blood called glycosylated haemoglobin (HbA1c), which gives an indication of how well the blood glucose is controlled. 
V študijah so merili raven snovi v krvi, imenovane glikozilirani hemoglobin (HbA1c), ki kaže, kako dobro je raven glukoze v krvi uravnana.
The company that markets Glustin will produce educational material for doctors prescribing the medicine, which will cover the possible risk of heart failure and bladder cancer with treatments that contain pioglitazone, the criteria for selecting patients and the need to review treatment regularly and stop treatment if patients are no longer benefiting. 
V njem bodo opisani možna tveganja za srčno popuščanje in raka sečnega mehurja pri zdravljenju s pioglitazonom, merila za izbiro bolnikov in potrebe po redni oceni zdravljenja ter prekinitev zdravljenja, če bolnikom ne koristi več.
This dose may need to be increased after one or two weeks to up to 45 mg once a day if better blood glucose (sugar) control is needed. 
Priporočeni začetni odmerek zdravila Glustin je 15 ali 30 mg enkrat na dan. Odmerek bo po enem ali dveh tednih morda treba povečati do 45 mg enkrat na dan, če je potrebno boljše uravnavanje glukoze (sladkorja) v krvi.
• on its own in patients for whom metformin (another diabetes medicine) is not suitable; 
• kot samostojno zdravilo pri bolnikih, za katere metformin (drugo zdravilo za zdravljenje sladkorne bolezni) ni primeren;